Lesson plan

Hydromorphinol

Hydromorphinol (RAM-320, 14-hydroxydihydromorphine), is an opiate analogue that is a derivative of morphine, where the 14-position has been hydroxylated and the 7,8- double bond saturated. It has similar effects to morphine such as sedation, analgesia and respiratory depression, but is twice as potent as morphine and has a steeper dose-response curve and longer half-life. It is used in medicine as the bitartrate salt (free base conversion ratio 0.643, molecular weight 471.5) and hydrochloride (free base conversion ratio 0.770, molecular weight 393.9) Hydromorphinol has also been discovered to occur naturally in trace amounts within opium, although this is a very rare occurrence. It is also called α-oxymorphol, and oxymorphol is itself a mixture of hydromorphinol and 4,5α-epoxy-17-methylmorphinan-3,6β,14-triol (β-oxymorphol) which is different at position 6 on the morphine carbon skeleton. Hydromorphinol was developed in Austria in 1932. In the United States, it was never available and is classified as a Schedule I drug with a DEA ACSCN of 9301. The salts in use are the bitartrate (free base conversion ratio 0.643) and hydrochloride (0.770). The 2014, national aggregate manufacturing quota was 2 grams, unchanged from prior years.…

Back to article

Article summary

Hydromorphinol (RAM-320, 14-hydroxydihydromorphine), is an opiate analogue that is a derivative of morphine, where the 14-position has been hydroxylated and the 7,8- double bond saturated. It has similar effects to morphine such as sedation, analgesia and respiratory depression, but is twice as potent as morphine and has a steeper dose-response curve and longer half-life. It is used in medicine as the bitartrate salt (free base conversion ratio 0.643, molecular weight 471.5) and hydrochloride (free base conversion ratio 0.770, molecular weight 393.9) Hydromorphinol has also been discovered to occur naturally in trace amounts within opium, although this is a very rare occurrence. It is also called α-oxymorphol, and oxymorphol is itself a mixture of hydromorphinol and 4,5α-epoxy-17-methylmorphinan-3,6β,14-triol (β-oxymorphol) which is different at position 6 on the morphine carbon skeleton. Hydromorphinol was developed in Austria in 1932. In the United States, it was never available and is classified as a Schedule I drug with a DEA ACSCN of 9301. The salts in use are the bitartrate (free base conversion ratio 0.643) and hydrochloride (0.770). The 2014, national aggregate manufacturing quota was 2 grams, unchanged from prior years.…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.